{"title": "BioNTech, Pfizer Push to Cancel Moderna Vaccine Tech Patents", "author": "Annelise Gilbert", "url": "https://news.bloomberglaw.com/ip-law/biontech-pfizer-push-to-cancel-moderna-vaccine-tech-patents", "hostname": "bloomberglaw.com", "description": "BioNTech SE and Pfizer Inc. urged the US Patent and Trademark Office to review and cancel two Moderna patents related to producing mRNA vaccines like those for Covid-19.", "sitename": "news.bloomberglaw.com", "date": "2023-08-29", "cleaned_text": "of mRNA technology,\" the companies said in [two](https://aboutblaw.com/baeD) [petitions](https://aboutblaw.com/baeC) seeking inter partes review filed at the patent office's administrative tribunal on Monday. US Patent Nos. [10,933,127](https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10933127) and [10,702,600](https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10702600) should be canceled because they are anticipated and obvious in light of prior art, they argued. The two challenged patents have \"unimaginably broad claims\" relating to mRNA composition and administration "}